Circadian Rhythm Sleep-Wake Disorders
Table of Contents
- Overview
- The Circadian Clock — Biology and Zeitgebers
- Melatonin and DLMO
- Delayed Sleep-Wake Phase Disorder
- Advanced Sleep-Wake Phase Disorder
- Irregular Sleep-Wake Rhythm Disorder
- Non-24-Hour Sleep-Wake Rhythm Disorder
- Shift Work Sleep Disorder
- Jet Lag Disorder
- Diagnosis
- Treatment — Light Therapy and Melatonin
- Key Research Papers
- Connections
Overview
Circadian Rhythm Sleep-Wake Disorders (CRSWDs) are a group of chronic conditions arising from a mismatch between the timing of the internal biological clock and the external world — or between the clock and a person's required sleep-wake schedule. Unlike insomnia, where total sleep is inadequate, CRSWDs typically involve sufficient sleep capacity but at the wrong time. Understanding these disorders begins with understanding how the circadian clock works and what happens when it falls out of sync.
The Circadian Clock — Biology and Zeitgebers
The master pacemaker of the human body is the suprachiasmatic nucleus (SCN), a paired cluster of approximately 20,000 neurons in the anterior hypothalamus, directly above the optic chiasm. The SCN generates a near-24-hour (circadian) rhythm through a transcriptional-translational feedback loop involving core clock genes:
- CLOCK and BMAL1: Transcription factors that activate Period (PER1, PER2, PER3) and Cryptochrome (CRY1, CRY2) genes
- PER and CRY proteins: Accumulate, inhibit CLOCK/BMAL1, then degrade — creating an approximately 24-hour oscillation
- REV-ERB and ROR: Additional feedback loop stabilizers
The intrinsic period of the human circadian clock averages approximately 24.2 hours — slightly longer than 24 hours. Without external time cues, the clock drifts later by approximately 12 minutes per day.
Zeitgebers (time givers) are environmental cues that entrain the clock to exactly 24 hours:
- Light is the dominant and most powerful zeitgeber. Detected by intrinsically photosensitive retinal ganglion cells (ipRGCs) containing the photopigment melanopsin, which is maximally sensitive to short-wavelength (blue) light (~470nm). The retinohypothalamic tract carries light signals directly from the eye to the SCN.
- Temperature: Core body temperature rhythm is tightly coupled to the clock; warm baths in the evening can shift phase.
- Food timing: Peripheral clocks in metabolic tissues (liver, gut, adipose) are entrained partly by meal timing — relevant for shift work metabolic consequences.
- Exercise: Modest phase-shifting effect depending on timing.
- Social cues: Human interaction and activity can reinforce or disrupt clock timing.
Melatonin and DLMO
Melatonin is produced by the pineal gland exclusively during darkness. It does not cause sleep directly — it signals darkness to the body, coordinating the circadian system. Key facts:
- Secretion begins about 2-3 hours before habitual sleep onset in a normally entrained individual
- Peaks around 2-3am, then declines
- Suppressed by light exposure, especially blue-wavelength light
- The Dim-Light Melatonin Onset (DLMO) — the time when melatonin rises to a threshold of 3-4 pg/mL under dim light conditions — is the gold-standard objective marker of circadian phase
- DLMO occurs approximately 2-3 hours before habitual sleep onset in healthy entrained adults
- In delayed sleep-wake phase disorder, DLMO shifts to midnight, 1am, or later
- Measurement: Saliva or blood sampled in dim light conditions every 30-60 minutes across 6+ hours in the evening
Why melatonin timing in treatment is not intuitive: In CRSWDs, melatonin is used as a chronobiotic (clock-shifting drug), not as a sedative. Low doses (0.5-1mg) taken several hours BEFORE the desired sleep time shift the clock earlier. Taking melatonin at bedtime (the typical patient assumption) is too late to shift the clock — it lands on a part of the phase-response curve where it has little effect on timing.
Delayed Sleep-Wake Phase Disorder (DSWPD)
The most common CRSWD. The endogenous circadian clock is set approximately 3-6+ hours later than conventional social time.
Presentation
- Cannot fall asleep until 2am, 3am, 4am, or later — not from anxiety or poor sleep hygiene, but because the clock is set too late
- Morning awakening is correspondingly late (10am-2pm)
- When able to sleep on their own schedule, sleep quality and total duration are normal
- The problem is inability to advance sleep timing to meet school or work demands
- Severe daytime sleepiness when forced to wake early; absent when sleeping on natural schedule
Epidemiology
- Prevalence approximately 0.17-0.4% in adults; up to 7-16% of adolescents
- Peak age of onset: adolescence (related to well-documented pubertal delay of circadian phase)
- Genetic basis: mutations in CRY1 gene extend the circadian period (e.g., CRY1 variant c.1657+3A>C → 24.8-hour period vs. 24.2-hour average)
- Often called "extreme night owls" by patients who have normalized years of social dysfunction
Common misdiagnoses: Depression, insomnia, ADHD, anxiety disorder. DSWPD patients may develop depression secondary to social impairment, but the primary disorder is circadian, not psychiatric.
Advanced Sleep-Wake Phase Disorder (ASPD)
The mirror image of DSWPD: the clock is set too early.
Presentation
- Irresistible sleepiness in early evening (6-8pm), inability to stay awake for normal social activities
- Spontaneous awakening at 3-5am, unable to return to sleep
- When allowed to sleep on natural schedule, sleep quality and duration are normal
- "Morning larks" at the clinical extreme
Epidemiology
- Less common than DSWPD; prevalence approximately 1% in middle-aged adults
- Increases markedly with age (older adults naturally phase-advance)
- Familial ASPD: autosomal dominant, high penetrance; mutations in PER2 (phosphorylation site, causing rapid PER2 degradation and shortened period) and CRY2
Irregular Sleep-Wake Rhythm Disorder (ISWRD)
Complete disorganization of circadian rhythm into multiple short sleep episodes scattered across 24 hours, with no dominant rest-activity cycle.
Presentation
- No consolidated sleep period
- Multiple short naps (2-4 hours) at irregular, variable times throughout day and night
- Chronic sleep deprivation symptoms
- Associated with loss of normal environmental time cues
Primary Associations
- Neurodegenerative disease: Alzheimer's disease (SCN neuron loss is documented pathologically), Parkinson's disease, Lewy body dementia
- Traumatic brain injury
- Intellectual disability with limited environmental structure
- Institutionalization without adequate light/dark cycling
Mechanism: Degeneration of the SCN itself, reduced retinal light sensitivity limiting photic input, and loss of behavioral zeitgebers all contribute.
Treatment: Structured light exposure (10,000 lux morning light), melatonin at consistent bedtime, structured social activity and meal timing; physical activity. Tasimelteon (suvorexant + melatonin agonist) studied in nursing home populations.
Non-24-Hour Sleep-Wake Rhythm Disorder (N24SWD)
The circadian clock fails to entrain to 24 hours and instead free-runs on its intrinsic period (typically 24.5-25 hours), causing sleep timing to drift approximately 30-60 minutes later every day.
Presentation
- Cyclically rotating sleep schedule
- Good sleep quality when sleeping on own schedule; insomnia and daytime sleepiness during weeks when schedule conflicts with social obligations
- Gradual cycle through all times of day over weeks to months
Primary association: The most common cause is total blindness (no light-dark perception). Without photic input via the retinohypothalamic tract, the SCN cannot entrain to 24 hours. Approximately 50-70% of totally blind individuals have some degree of N24SWD.
Sighted N24SWD is rare and less understood; may represent an extreme of delayed phase with very long intrinsic period.
Treatment
- Tasimelteon (Hetlioz): FDA-approved in January 2014 — the first drug specifically approved for N24SWD. Melatonin receptor agonist (MT1 and MT2), high-affinity binding. 20mg taken at the same clock time each night entrains the blind circadian system. Clinical trials demonstrated entrainment in approximately 20% of patients; significantly more achieved partial night-time sleep improvement.
- Melatonin: 0.5-10mg at target bedtime time; varying evidence.
- Timed social zeitgebers for sighted N24SWD (meal timing, exercise timing, structured social cues).
Shift Work Sleep Disorder (SWSD)
Chronic misalignment between the circadian clock and required work schedule in people working non-standard hours (night shifts, rotating shifts, early morning shifts).
Prevalence: 10-38% of shift workers develop SWSD; 15-20% of the working population works non-standard hours.
Diagnostic criteria: Insomnia or excessive sleepiness coinciding with shift work schedule; present for at least 3 months; associated with impaired function.
Health Consequences of Chronic Shift Work Misalignment
- Metabolic syndrome and type 2 diabetes (disrupted glucose metabolism)
- Cardiovascular disease (higher rates of hypertension, MI, stroke)
- GI disorders
- Cancer risk: Breast cancer risk significantly elevated in female night shift nurses (shift work classified Group 2A carcinogen by IARC)
- Reduced immune function
- Mental health consequences (depression, anxiety)
Specific challenges: Night shift workers sleep against their biological clock (daytime sleep shorter, less refreshing); rotating shifts prevent adaptation; morning commute light exposure after night shift defeats adaptation.
Treatment
- Scheduled sleep timing (sleep as soon as possible after shift ends; use blackout curtains, eye mask)
- Light management: bright light exposure during night shift (delays clock); avoid morning light on commute home (blue-blocking glasses)
- Melatonin 0.5-3mg before daytime sleep
- Modafinil/armodafinil (FDA-approved for SWSD) — wakefulness promotion during night shift
- Shift scheduling advocacy: rotating shifts should rotate clockwise (delay direction, easier than advance); allow adaptation time
Jet Lag Disorder
Transient circadian misalignment caused by rapid transmeridian travel crossing multiple time zones.
Pathophysiology: The SCN and peripheral clocks require approximately 1 day per time zone crossed to re-entrain. During the transition period, internal circadian phase is misaligned with the new local time.
Direction Matters
- Eastward travel requires phase advance (sleeping earlier) — against the clock's natural tendency to delay; most difficult direction; rule of thumb: 1.5 days per time zone crossed to fully adapt
- Westward travel requires phase delay (sleeping later) — aligns with the natural lengthening tendency; easier; approximately 1 day per time zone
Symptoms: Insomnia at destination night, daytime sleepiness, cognitive impairment, GI disturbances (gut clocks are also disrupted), malaise, irritability.
Treatment
- Light exposure at destination: morning light for eastward travel (advances clock); evening light for westward
- Melatonin: 0.5-5mg at destination bedtime for 3-5 nights; timing is key
- Pre-travel phase shifting (advance schedule 2-3 days before eastward flights)
- Avoid excessive alcohol and caffeine during travel
- Short-acting hypnotics for 1-2 nights at destination if needed
Diagnosis
Sleep Diary (mandatory, minimum 2 weeks)
The foundation of CRSWD assessment. Patient records sleep/wake times, nap times, subjective sleep quality, and light exposure. Reveals the characteristic pattern (consistent delayed or advanced timing, irregular scatter, or progressive drift).
Actigraphy
Wrist-worn accelerometer worn for 7-14 days. Records movement continuously; sleep/wake inferred from activity patterns. Provides objective confirmation of sleep diary findings. Gold-standard for demonstrating free-running or irregular patterns. Now widely available and validated.
Dim-Light Melatonin Onset (DLMO)
The most objective circadian phase marker. Blood or saliva samples collected every 30-60 minutes for 6+ hours starting in the early evening under dim light conditions (<10 lux). DLMO typically occurs approximately 2-3 hours before habitual sleep onset. Delayed DLMO (e.g., midnight or later) confirms DSWPD; earlier DLMO confirms ASPD. Not yet widely available clinically; primarily used in research and specialist centers.
Polysomnography
Not routinely required for CRSWD diagnosis but indicated when coexisting sleep disorders (particularly OSA) are suspected. OSA is a common comorbidity and can complicate the clinical picture.
Chronotype Questionnaires
Munich Chronotype Questionnaire (MCTQ) and Morningness-Eveningness Questionnaire (MEQ) provide validated self-report chronotype assessment. Useful screening but insufficient alone for clinical diagnosis.
Treatment — Light Therapy and Melatonin
Bright Light Therapy
10,000 lux (or 2,500 lux for longer duration) commercial light therapy lamps. Timing determines direction of phase shift:
- DSWPD: morning light immediately upon awakening (7-8am) advances the clock, shifting sleep earlier. Must occur at the appropriate circadian phase; too early (before habitual wake time) causes phase delay instead.
- ASPD: evening light (7-9pm) delays the clock, shifting sleep later.
- Duration: typically 30 minutes at 10,000 lux or 60 minutes at 2,500 lux.
- Light must enter the eyes (not just the skin); no UV required; do not look directly at the lamp.
- Blue-blocking glasses in the evening are a complementary intervention to reduce inappropriate evening light exposure.
Melatonin (Used as Chronobiotic, Not Sedative)
- DSWPD: 0.5-1mg at 5-7pm (5-6 hours before desired sleep onset; approximately 2 hours before natural DLMO) — this timing lands on the advance portion of the melatonin phase-response curve. Higher doses (3-5mg) at the same time also work but produce more adverse effects.
- ASPD: 0.5-3mg in the morning (after wake) to delay clock — rarely used clinically.
- General: use the lowest effective dose (0.5mg is often sufficient); sustained-release vs. immediate-release has different applications; over-the-counter products are often 10x the effective dose.
Chronotherapy for DSWPD
Progressive delay of sleep time by 3 hours every 2 days until the desired schedule is reached (e.g., start at 3am → 6am → 9am → noon → 3pm → 6pm → 9pm → midnight → 3am → midnight [goal]). After reaching target, must maintain strict wake times. Labor-intensive; requires 1-2 weeks; effective when completed.
Tasimelteon (Hetlioz)
Melatonin receptor agonist (MT1/MT2). FDA-approved for N24SWD in totally blind patients. Under investigation for DSWPD and ISWRD in additional populations. 20mg at the same clock time each night.
Combined Approach for DSWPD
The most effective treatment combines morning bright light + evening low-dose melatonin + strict wake time + blue-light avoidance in the evening. Relapses are common when behavioral modifications are discontinued.
Key Research Papers
- Sack RL, et al. (2007). Circadian rhythm sleep disorders, Part I: Basic principles, shift work, and jet lag disorders. Sleep, 30(11), 1460-1483. PMID 18041481
- Patke A, et al. (2017). Mutation of the human circadian clock gene CRY1 in familial delayed sleep phase disorder. Cell, 169(2), 203-215. PMID 28388406
- Lockley SW, et al. (2015). Tasimelteon for non-24-hour sleep-wake disorder in totally blind people. Lancet, 386(10005), 1754-1764. PMID 26466051
- Mundey K, et al. (2005). Phase-dependent treatment of delayed sleep phase syndrome with melatonin. Sleep, 28(10), 1271-1278. PMID 16295219
- Morgenthaler TI, et al. (2007). Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders. Sleep, 30(11), 1445-1459. PMID 18041480
- Roenneberg T, et al. (2012). Social jetlag and obesity. Current Biology, 22(10), 939-943. PMID 22578422
- Takahashi JS (2017). Transcriptional architecture of the mammalian circadian clock. Nature Reviews Genetics, 18(3), 164-179. PMID 27990019
- Lewy AJ, et al. (2006). The circadian basis of winter depression. Proceedings of the National Academy of Sciences, 103(19), 7414-7419. PMID 16648247
- Czeisler CA, et al. (1999). Stability, precision, and near-24-hour period of the human circadian pacemaker. Science, 284(5423), 2177-2181. PMID 10381883
- Vetter C, et al. (2016). Association between rotating night shift work and risk of coronary heart disease. JAMA, 315(16), 1726-1734. PMID 27115377
- Abbott SM, et al. (2014). Circadian disruption and human health. Journal of Clinical Investigation, 124(6), 2466-2472. PMID 24892705
- Auger RR, et al. (2015). Clinical practice guideline for the treatment of intrinsic circadian rhythm sleep-wake disorders. Journal of Clinical Sleep Medicine, 11(10), 1199-1236. PMID 26414986